UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

This is an investigator-initiated trial to evaluate the safety and efficacy ofuniversal allogeneic anti-CD19/BCMA CAR T-cells in Patients With Relapse/Refractory Autoimmune Diseases.

Study intervention consists of a single infusion of universal allogeneic CART-cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.

Inclusion criteria

• Age ≥ 18 years old (inclusive), regardless of gender.
• Positive expression of CD19 on peripheral blood B cells confirmed by flow cytometry.
• Adequate hepatic, renal and bone marrow function.
• Participants with relapsed or refractory autoimmune diseases, Including SLE or SSc.

Exclusion criteria

• Participants with a history of severe drug allergies or allergic constitutions.
• Presence or suspicion of uncontrolled or treatment-required fungal, bacterial, viral, or other infections.
• Participants with insufficient cardiac function.
• Participants with congenital immunoglobulin deficiencies.
• History of malignancy within five years.